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Galectin-3 (Gal-3) is considered as a myocardial fibrosis biomarker with prognostic value in
heart failure (HF). Since aldosterone is a neurohormone with established fibrotic properties,
we aimed to investigate if mineralocorticoid receptor antagonists (MRAs) would modulate
the prognostic value of Gal-3.
Methods
The IBLOMAVED cohort comprised 427 eligible chronic HF patients (CHF) with echocardi-
ography and heart failure biomarkers assessments (BNP). After propensity score matching
CHF patients for cardiovascular risk factors, to form balanced groups, Gal-3 levels were
measured at baseline in plasma from patients treated with MRAs (MRA-Plus, n=101) or
not (MRA-Neg, n=101). The primary end point was all-cause mortality with a follow-up
of 3 years.
Results
Gal-3 in plasma from these patients were similar with median values of 14.0 ng/mL [IQR,
9.9–19.3] and 14.4 ng/mL [IQR, 12.3–19.8] (P = 0.132) in MRA-Neg and MRA-Plus, respec-
tively. Patients with Gal-317.8 ng/mL had an HR of 1 (reference group) and 1.5 [0.4–5.7]
in MRA-Neg and MRA-Plus, respectively (p=0.509). Patients with Gal-3 17.8 ng/mL had
an HR of 7.4 [2.2–24.6] and 9.0 [2.9–27.8] in MRA-Plus and MRA-Neg, respectively
(p=0.539) and a median survival time of 2.4 years [95%CI,1.8–2.4]. Multivariate Cox propor-
tional hazard analysis confirmed that MRA and the interaction term between MRA treatment
and Gal-3>17.8 ng/mL were not factors associated with survival.
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Conclusions
MRA treatment did not impair the prognostic value of Gal-3 assessed with a 17.8 ng/mL cut
off. Gal-3 levels maintained its strong prognostic value in CHF also in patients treated with
MRAs. The significance of the observed lack of an interaction between Gal-3 and treatment
effect of MRAs remains to be elucidated.
Introduction
Galectin-3 (Gal-3), a member of the family of beta-galactoside-binding lectins, is a 30 kDa gly-
coprotein with a carbohydrate recognition domain of 130 amino acids that plays a role in
many biological processes, including fibrosis [1–3]. Gal-3 provides a link between inflamma-
tion and fibrosis. Macrophage-derived Gal-3 was first suggested to be an important mediator
in cardiac fibrosis by inducing cardiac fibroblast proliferation and collagen deposition resulting
in HF development and progression [4]. Gal-3 was proposed as a biomarker of heart fibrosis
that could predict outcome of heart failure (HF) [5]. In several cohorts of acute HF [6, 7] and
chronic HF [8], Gal-3 was shown to be a powerful predictor of mortality. In most studies, Gal-
3 had independent prognostic value when corrected for common risk factors such as age, gen-
der and (NT-pro)BNP. Further, elevated Gal-3 in subjects from the general population has
been associated with increased mortality [9, 10] and new-onset HF [10]. Recently, Gal-3 was
approved by the US Food and Drug Administration as a new biomarker for HF risk stratifica-
tion and has received a Class IIb recommendation for additive risk stratification in AHA/ACC
guidelines [11].
Gal-3 has established interaction with specific pathophysiology in the HF syndrome. For in-
stance, a strong interaction with kidney function seems to exist [12]. Further, in HF patients,
Gal-3 levels have been shown to be significantly correlated with serum markers of cardiac ex-
tracellular matrix turnover [13]. Experimental evidences clearly link Gal-3 to fibrosis in the
heart [14], but also renal [15], liver [16], and lung fibrosis [17].
Aldosterone is a central player in fibrosis [18]. Gal-3 has been shown to mediate the
aldosterone-induced fibrosis response [19]. Therefore, we aimed to evaluate if the prognostic
value of Gal-3 in chronic heart failure patients, either treated or not treated by mineralocorti-
coid receptor antagonists (MRAs), would be different. MRAs are recommended in the ESC
and AHA/ACC guidelines as an additional therapeutic option to improve outcomes in pa-
tients with HF and reduced ejection fraction [11, 20]. The anti-fibrotic action of MRAs has
been proposed as one of the mechanisms linked to the clinical benefit of aldosterone blockade
[21]. A subanalysis of the RALES study showed that high baseline serum levels of markers of
matrix turnover were significantly associated with poor outcome, and these markers were
amenable to spironolactone therapy [22]. Given the intimate relation between aldosterone, fi-
brosis, and Gal-3, and the differential effects of MRAs in patients with active fibrogenesis, we
hypothesized that the predictive value of Gal-3 in HF patients may be influenced by the use of
MRAs. A recent subanalysis from the HF-ACTION study, however, showed no differential re-
sponse of MRAs in patients with Gal-3 below or above the FDA-cleared cutpoint of 17.8 ng/
mL [23]. Because this study was limited to the pre-specified inclusion/exclusion criteria of the
HF-ACTION study, to date, an interaction between effects of anti-aldosterone treatment and
Gal-3 has not been definitely demonstrated in HF patients. Our objective was to investigate
the effect of MRAs on the prognostic value of Gal-3 in a contemporary cohort of chronic HF
patients routinely seen at a University Hospital in France.
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Patients and Methods
Ethics statement
The IBLOMAVED study was registered in a clinical database (ClinicalTrials.gov
NCT01024049) and conform to the ethical guidelines of the 1975 Declaration of Helsinki. The
protocol was approved by the institution’s human research (COSSEC) and regional ethics com-
mittee (Comite de Protection des Personnes (CPP) # DC 2008–452). Written informed consent
was obtained from all participants and/or their legally authorized representatives.
Study design
This is a retrospective investigation of interaction between MRA treatment and the prognostic
value of Gal-3 in a subset of CHF patients from the IBLOMAVED study [24]. The IBLO-
MAVED cohort comprised 686 patients admitted between July 2007 and May 2013 to the car-
diology department at Rangueil Hospital, Toulouse, France. Inclusion criteria required absence
of stroke within the last 6 months, acute liver failure within the last 6 months or known chronic
hepatic failure (alanine aminotransferase or aspartate amino transferase 5 times the upper reg-
ular limits), history for alcohol abuse or drug addiction, cancer or a diagnosis of cancer within
5 years, history of recent or current drug or alcohol abuse, participation in any clinical trial
within 30 days prior to admission, hematological pathology (myelodegenerative syndrome, se-
vere anemia (Hb, 8 g / 100 mL) or severe neutropenia (neutrophile count, 1000 cells /mL),
thrombocypenia (platelet count,7500 plts/mL). Baseline demographic data, admission vital
signs, clinical history, assessment of cardiovascular risk factors and admission medication were
recorded. Biochemical data including BNP levels were obtained at admission. Venous blood
samples were obtained during the morning within 24 hours following admission. In this co-
hort, 427 patients had a medical history of HF at admission. This cohort comprised patients
from all AHA/ACC HF classification groups to provide a wide spectrum of patients for HF bio-
markers studies. All the 686 patients underwent transthoracic echocardiography for left ven-
tricular ejection fraction (LVEF) assessment. We used a threshold value of LVEF< 45% to
select stable systolic chronic heart failure (CHF) patients (n = 427). Because of the multivariate
filtering (propensity score), patients with missing data were discarded (n = 74). Patients were
sorted into two groups: treated by mineralocorticoid receptor antagonists (MRA-Plus; n = 127)
or not treated with this drug (MRA-Neg; n = 230). Finally, 101 patients were selected in each
group by the propensity score matching method.
Primary end point
The primary end point was all-cause mortality during follow-up.
Measurement of galectin-3
Galectin-3 (Gal-3) was measured at baseline using an automated immunoassay on the VIDAS
analyzer (bioMérieux, Marcy l’Etoile, France). The VIDAS Galectin-3 kit quantitatively mea-
sures the concentration of human galectin-3 levels in EDTA plasma. This assay has a measur-
ing range of 3.3 to 100 ng/mL, high repeatability (CV about 1%) and reproducibility (CV about
5%), without cross-reactivity with collagens or other members of the galectin family. Common-
ly used HF medication does not interfere with the assay.
Statistical analysis
Analyses were performed using Statistical R (version 3.0.1; http://www.r-project.org) or Med-
calc (version 12.7.7; Medcalc Software bvba, Ostend, Belgium). Continuous variables were
Galectin-3 and Mineralocorticoid Receptor Antagonists
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expressed as means ± standard deviation for normally distributed data or as medians with 95%
confidence interval. Propensity scores were generated from logistic regression analysis
(MatchIt package version 2.4.21)[25] with MRA treatment as dependent variable and included
age, gender, obesity, diabetes, arterial hypertension (AHT), dyslipidemia, ischemic cardiomy-
opathy (ICM), left ventricular ejection fraction (LVEF), heart rate (HR), blood creatinine con-
centration (Creat) as predictors. Pairs of MRA-Neg and MRA-Plus patients were formed with
propensity scores differing by at most 0.25 of the standard deviation of the logit of the propen-
sity score [26]. Non parametric Mann-Whitney rank sum test and Chi-square test were used
for statistical testing of continuous and categorical variables, respectively. Survival curves were
constructed using the Kaplan-Meier method and compared with the log-rank test. Patients
were categorized based on a Gal-3 threshold value of 17.8 ng/mL [27]. Additional categoriza-
tion was made based on MRA treatment and patients not using MRAs with Gal-3 17.8 ng/
mL constituted the reference group (HR = 1.0). Univariate Cox regression was applied to evalu-
ate the hazard ratio of covariates adjusted for age and gender. Mutivariate Cox proportional
hazards models 1 to 3 were performed with variables that obtained a p<0.2 as result of the uni-
variate analysis. Stepwise regression was performed with the variable entered if its associated
significance level was less than P< 0.1 and removed if its associated significance level was
greater than P> 0.2 in the regression model.
Results
In the CHF subset of the IBLOMAVED cohort, about one third of the patients were treated by
MRAs (123/353). The propensity score matching method was used to balance demographic
and clinical criteria between MRA-Neg and MRA-Plus patients (Table 1). After matching, the
selected 101 pairs of MRA-Neg and MRA-Plus patients presented similar characteristics for
the matched variables. Treatments with beta blockers, ACE inhibitors and loop diuretics (Furo-
semide) were more frequently used in MRA-Plus patients. BNP measured at admission were
similar in both groups (Table 1). Gal-3 retrospectively measured in plasma of these groups of
patients were similar with median values of 14.0 ng/mL [IQR, 9.9–19.3] and 14.4 ng/mL [IQR,
12.3–19.8] (P = 0.132) in MRA-Neg and MRA-Plus, respectively (Table 1).
MRA-neg, Patients not treated by mineralocorticoid receptor antagonist; MRA-plus, Pa-
tients treated by mineralocorticoid receptor antagonist; AHT, arterial hypertension; ICM, is-
chemic cardiomyopathy; Creat: creatinine; LVEF, left ventricular ejection fraction; BNP, brain
natriuretic peptide; Gal-3, Galectin-3; HR: heart rate; NYHA, New York Heart Association
classes; SGOT, serum glutamic oxaloacetic transaminase; ARA II, angiotensin II receptor an-
tagonists; AVK drugs, Anti vitamin K drugs; ACE inhibitors, angiotensin-converting-enzyme
inhibitors. Propensity score was used to match patients based on the following variables: age,
gender, obesity, diabetes, arterial hypertension (AHT), dyslipidemia, ischemic cardiomyopathy
(ICM), left ventricular ejection fraction (LVEF), blood creatinine concentration (Creat). Acute
pulmonary edema occurring during the last month preceding the inclusion.
Median follow-up was 1.13 years (14 months) [IQR, 0.46–1.65 (6–20 months)]. Out of the
202 patients, 31 (15%) were censored for primary endpoint and 171 (85%) were end-of-study
censored. The concentration of Gal-3 was higher in patients who died than in survivors with
median values of 29.6 ng/mL [IQR, 14.8–33.1] and 13.8 ng/mL [IQR, 10.5–17.6] for the former
and later, respectively, P<0.001. Patients were stratified according to baseline Gal-3 concentra-
tion 17.8 ng /mL which corresponds to the cut off with the low risk of adverse outcome in
HF patients [8]. Out of the 202 patients, 140 (69%) had a Gal-3 concentration 17.8 ng/mL.
Survival analysis showed that patients with a Gal-3>17.8 ng/mL presented a higher risk of
death with a HR of 7.42 [95%CI, 5.47–27.96] and a median survival time of 2.4 years [95%
Galectin-3 and Mineralocorticoid Receptor Antagonists
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CI,1.8–2.4] (Fig. 1A). Similar HR values were obtained with univariate Cox proportional haz-
ard analysis adjusted for age and gender (Table 2) or with different multivariate models which
included clinical, paraclinical and medication factors (Table 3). Clearly, MRA treatment was
not associated with survival of patients (Table 2). Indeed, the prognostic value of Gal-3 was not
significantly affected by MRA treatment (Fig. 1B). Multivariate Cox proportional hazard analy-
sis confirmed that MRA and the interaction term between MRA treatment and Gal-3>17.8
ng/mL were not factors associated with survival (see Model 4, Table 3).
HR value for Gal-3> 17.8 ng/mL adjusted for age, gender and in model 1 (+ creat, BNP,
serum sodium) or in model 2 (+ ARA II, Beta blockers, ACE inhibitors, Furosemide) or in
model 3 (+ LVEF and HR). Model 4, HR value for Gal-3> 17.8 ng/mLadjusted for age, gender,
MRA and interaction term MRAGal-3>17.8 ng/mL (0.87 (95% CI, 0.37–2.05), p = 0.750 and
0.57 (95% CI, 0.13–3.07). HR values for MRA and interaction term respectively). Model 5, HR
values for Gal-3> 17.8 ng/ml determined using stepwise method for selection of variables in-
cluded in model 1 to 3.
Table 1. Baseline characteristics of CHF patients.
MRA-Neg MRA-Plus
(n = 101) (n = 101) P
Age, y ±SD 59 ± 15 57 ± 11 0.299
Gender, % female 23 20 0.731
Obesity, % 23 25 0.869
Diabetes, % 23 22 1.000
AHT, % 36 33 0.767
Dyslipidemia, % 41 35 0.468
ICM, % 41 41 0.886
LVEF, % [95% CI] 30 [28–34] 30 [26–31] 0.346
LVEF < 30, % 41 46 0.571
HR, bpm [95% CI] 70 [69–80] 72 [70–76] 0.554
NYHA 2 55 60 0.627
NYHA 3 32 32 0.879
NYHA 4 12 8 0.541
ICM, % 41 41 0.886
Acute pulmononary* 34 34 0.882
ARA II 13 13 0.834
Calcium blockers 7 7 0.782
AVK drugs 34 35 0.961
Antiplatelet Agents 39 46 0.325
Statines 49 44 0.572
Beta blockers 67 86 0.003
ACE inhibitors 60 80 0.003
Furosemide 60 90 <0.001
Creat, μM [95% CI] 95 [90–102] 97 [88–102] 0.910
Serum sodium, mM 139 [137–139] 137 [137–138] 0.005
SGOT, IU/l [95% CI] 28 [25–32] 27 [25–30] 0.757
BNP, pg/ml [95% CI] 399 [210–206] 364 [261–563] 0.724
Gal-3, ng/ml [95% CI] 14.0 [9.9–19.3] 14.4 [12.3–19.8] 0.132
doi:10.1371/journal.pone.0119160.t001
Galectin-3 and Mineralocorticoid Receptor Antagonists
PLOS ONE | DOI:10.1371/journal.pone.0119160 March 18, 2015 5 / 10
Discussion
Our study confirms previous observations on the prognostic value of Gal-3 in patients with HF
[27]. Our cohort consisted of HF patients with systolic HF, but even in patients with preserved
ejection fraction Gal-3 was shown to be prognostic [28]. Moreover, Gal-3 changes in patients
were shown to be a strong prognostic indicator [29]. In addition, Gal-3 levels have a potential
role in early detection of myocardial structural and functional alterations [30] and risk stratifi-
cation in HF [31, 32].
Since patients with low Gal-3 levels were shown to benefit from statin therapy [33], this ob-
servation suggested that Gal-3 levels could be used to predict response to therapies. Therefore,
we assessed the influence of MRA treatment on the prognostic value of Gal-3. Clearly, in our
cohort MRA treatment did not alter the prognostic value of Gal-3. We also observed that MRA
treatment did not alter mortality in our cohort. Several clinical studies have proposed that
MRA treatment reduced all-cause death in HF [34–37] but other studies failed to show a reduc-
tion in mortality [23, 38]. However, the positive studies were conducted in very large cohorts
and the beneficial effect of MRA may not be observed in the later rather small cohorts. Fiuzat
et al. have also investigated the relationship between Gal-3 levels and the use of MRA in HF
Fig 1. Survival analysis of cohort by the combination of MRA treatment and Gal-3 stratification. (A) Patients were categorized in two groups according
to baseline concentration of Gal>17.8 ng/mL. Hazard ratio (HR) for patients with Gal-3> 17.8 ng/mL was 7.42 [95%CI, 5.47–27.96]; p<0.0001. (B)
Comparison of HR between the four groups of patients, according to the MRA treatment (MRA-Neg or MRA-Plus) and the Gal-3 level (Gal-317.8 ng/mL or
Gal-3>17.8 ng/mL). P values of differences between groups are indicated. The group of patients with Gal-3 17.8 ng/mL and without MRA treatment
constitutes the reference group (HR = 1).
doi:10.1371/journal.pone.0119160.g001
Galectin-3 and Mineralocorticoid Receptor Antagonists
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[23]. Despite the fact that this was a much larger cohort, the authors did not show a significant
difference in outcomes of patients on MRA, even after adjustment for important clinical vari-
ables. Accordingly, as observed in our study, the prognostic value of Gal-3 in this study was not
impaired by MRA use. We believe that a prospective randomized multicentric study will be re-
quired to further investigate the possible interactions of MRA and Gal-3, and to draw final con-
clusions whether Gal-3 can be useful to select patients who will benefit fromMRAs.
Table 2. Univariate Cox proportional hazards analysis.
HRa [95% CI] P
(n = 202)
Age, per 10 y 1.24 [0.92–1.67] 0.156
Gender, male = 1 0.51 [0.18–1.48] 0.224
Obesity 0.64 [0.25–1.66] 0.364
Diabetes 1.28 [0.57–2.85] 0.547
AHT 1.55 [0.75–3.17] 0.233
Dyslipidemia 0.90 [0.43–1.88] 0.786
ICM 1.42 [0.70–2.90] 0.331
Acute pulmononary * 1.48 [0.67–3.26] 0.342
LVEF per 5% 0.82 [0.69–0.98] 0.029
HR, per 5 unit 1.15 [1.04–1.26] 0.005
MRA 0.98 [0.48–1.98] 0.950
ARA II 0.19 [0.03–1.39] 0.103
Calcium blockers 0.94 [0.22–4.02] 0.940
AVK drugs 1.04 [0.49–2.21] 0.916
Antiplatelet Agents 1.03 [0.50–2.09] 0.943
Statines 0.71 [0.34–1.46] 0.355
Beta blockers 0.35 [0.15–0.79] 0.002
ACE inhibitors 0.51 [0.25–1.05] 0.070
Furosemide 2.78 [1.28–6.03] 0.042
Creatinine per 10 μM 1.11 [1.02–1.20] 0.013
Serum sodium per mM 0.82 [0.76–0.87] <0.001
BNP per 100 pg/ml 1.09 [1.05–1.13] <0.001
Gal-3 > 17.8 ng/ml 7.25 [3.28–16.03] <0.001
Gal-3 per 10 ng/ml 2.45 [1.91–3.15] <0.001
a Hazard ratio adjusted for age and gender. In bold variables with p < 0.2 implemented in the multivariate
cox proportional hazards analysis.
doi:10.1371/journal.pone.0119160.t002
Table 3. Multivariate cox proportional hazards analysis.
HR 95%CI P
Model 1 4.75 1.99–11.36 <0.001
Model 2 7.01 3.01–16.30 <0.001
Model 3 6.07 2.62–14.02 <0.001
Model 4 7.25 3.28–16.03 <0.001
Model 5 5.75 1.97–16.81 <0.001
doi:10.1371/journal.pone.0119160.t003
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Study limitations
This study was retrospective and designed with the IBLOMAVED cohort. Despite the compar-
ative groups were optimized with the use of the propensity score matching, the analysis was
performed on a limited number of patients.
Conclusions
In our cohort of chronic stable systolic HF, baseline Gal-3 has a strong independent prognostic
value irrespective of treatment with MRAs. The significance of the observed lack of an interac-
tion between Gal-3 and treatment effect of MRAs remains to be elucidated.
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